Nionyx Bio is redefining gene therapy for the kidney. Its proprietary AAV capsid platform is designed to deliver one-time, tissue-targeted therapies with improved safety, precision, and scalability. Backed by top-tier investors and led by a team of gene therapy pioneers, Nionyx is building the AAV Kidney Atlas to de-risk development and accelerate a new class of renal gene therapies.